公司概述
Calidi Biotherapeutics, Inc. operates as a clinical stage immuno-oncology company dedicated to developing allogeneic stem cell-based and enveloped virus platforms designed to potentiate and deliver oncolytic viruses within the United States. The enterprise functions within the Healthcare sector, specifically targeting the Biotechnology industry, which implies a focus on high-risk, high-reward research and development activities aimed at advancing cancer therapies. The company's total market capitalization stands at $2.81M, supported by an annual revenue that is not currently disclosed, and an operational workforce consisting of 29 employees. These financial and structural metrics indicate that Calidi Biotherapeutics is a micro-cap entity operating with a minimal headcount, suggesting that its value proposition relies heavily on the successful advancement of its product pipeline rather than established commercial sales or a large-scale infrastructure.
财务健康
The company reports a net income of $-25,579,000 for the trailing twelve months, while EBITDA sits at $-18,589,000, and revenue figures are unavailable for the trailing twelve months. The significant negative net income relative to the unavailable revenue data reveals a cost structure dominated by substantial research and development expenditures or operational losses typical of clinical-stage biotechnology firms before commercialization. Free cash flow is recorded at $-11,853,875, indicating that the company is consuming cash reserves to fund its operations and clinical trials rather than generating positive operating cash flow. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the pre-revenue or loss-making stage where traditional profitability measures do not yet apply to the business model. On the balance sheet, the company holds $5.60M in cash against $2.56M in debt, resulting in a debt-to-equity ratio of 68.21 which suggests a leveraged position relative to its equity base. The current ratio stands at 1.59, indicating that the company possesses sufficient current assets to cover its current liabilities, thereby maintaining a baseline of short-term liquidity despite the overall cash burn. Return on Equity is calculated at -700.6% and Return on Assets at -109.8%, metrics that reveal that management is currently generating negative returns on shareholder capital and total assets due to the heavy investment phase required to advance clinical products.
估值评估
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -0.29, a metric that implies the market is pricing in expected losses or is utilizing an alternative calculation method for companies in deep development. The price-to-book ratio is 0.51, indicating that the market values the company at half of its book value, which often suggests that the market perceives significant risks or that the asset base may not be fully capitalized on paper. The price-to-sales ratio is N/A because revenue is not yet material, and the EV/EBITDA stands at 0.01, suggesting that valuation multiples based on earnings are not applicable at this stage of development. The stock's 52-week high is $19.20 and the 52-week low is $0.21, providing a range within which the stock trades, though the current trading price relative to this specific range requires calculation based on the latest available share price not provided in the facts. The beta value is 1.42, which signifies that the stock's price volatility is approximately 42% higher than the broader market, reflecting the inherent instability of small-cap biotechnology equities.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both N/A, indicating that the company has not yet achieved consistent commercial revenue streams to calculate meaningful growth rates. Since earnings are negative and revenue is N/A, the comparison of earnings growth versus revenue growth is not applicable in a traditional sense, as the company is in a pre-profitability phase where growth is measured in clinical milestones rather than financial expansion. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available cash flow back into its research and development activities rather than distributing income to shareholders. Consequently, the overall growth and income profile of Calidi Biotherapeutics is characterized by zero current income generation and a reliance on future clinical trial successes to transition from a cash-burning entity to a commercially viable biotechnology firm.